Clinical Evidence

Exploratory Study of Curcumin isolated from Turmeric Curcuma longa, the Putative Histone Deacetylase Inhibitor, as added-on strategy to antipsychotics in treating negative symptoms and Neuro-cognitive deficits in Schizophrenia
Adv Res J Multidisciplinary Discovery 2019; 40(2): 6-15
Data from epidemiological research indicates that both the individual’s genes and the environment influence the pathophysiology of schizophrenia. Molecular mechanisms mediating the interplay between genes and the environment are likely to have a significant role in the onset of the disorder. Recent work indicates that epigenetic mechanisms, or the chemical markings of the DNA and the surrounding histone proteins, remain labile through the lifespan and can be altered by environmental factors. Thus, growing evidence suggests epigenetic dysregulation may play a role in schizophrenia. Hence modulation of epigenetic factors can result in avenue for proper management of schizophrenia.

To evaluate the potential therapeutic benefit of curcumin against schizophrenia through epigenetic modification.


The study was an open-label-parallel-group-randomized study in schizophrenia patients. The subjects were randomized into Group 1 (SupercurcuminTM daily 1 gm) and Group 2 (SupercurcuminTM 4 gm daily) for 16 weeks.

  • We found that Group 1 Group 2 significantly improved the total and general psychopathology sub-scales pf PANSS (Positive and Negative Symptoms scale)
  • PANSS-general psychopathology was significant for Group 1
  • Cohen’s d-effect size favored curcumin treatment
  • Curcumin was well tolerated with no serious adverse events

The study demonstrated the safety and potential benefits of curcumin combined with piperine in schizophrenia.